Efavirenz conceptions and regimen management in a prospective cohort of women on antiretroviral therapy

Infectious Diseases in Obstetrics and Gynecology

Volumn 2012, Issue , 2012, Pages

  Schwartz, Sheree ^a,b   Taha, Taha E ^b   Venter, Willem Daniel Francois ^a   Mehta, Shruti ^b   Rees, Helen ^a   Black, Vivian ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ADULT; CD4+ T LYMPHOCYTE; CONCEPTION; FEMALE; FERTILITY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONAL CONTRACEPTION; HUMAN; LIVE BIRTH; LIVER INJURY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PATIENT CARE; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; PREGNANCY TERMINATION; PREGNANCY TEST; PREGNANT WOMAN; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPRODUCTION; REVIEW; SOUTH AFRICA; SPONTANEOUS ABORTION; VIRUS LOAD; ADOLESCENT; ARTICLE; CLINICAL TRIAL; DRUG SUBSTITUTION; FIRST TRIMESTER PREGNANCY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MULTICENTER STUDY;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; DRUG SUBSTITUTION; FEMALE; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; PREGNANCY; PREGNANCY RATE; PREGNANCY TRIMESTER, FIRST; PROSPECTIVE STUDIES; SOUTH AFRICA; YOUNG ADULT;

EID: 84863710595     PISSN: 10647449     EISSN: 10980997     Source Type: Journal    
DOI: 10.1155/2012/723096     Document Type: Review

References (23)

1. Gray R. H., Wawer M. J., Serwadda D., Sewankambo N., Li C., Wabwire-Mangen F., Paxton L., Kiwanuka N., Kigozi G., Konde-Lule J., Quinn T. C., Gaydos C. A., McNairn D., Population-based study of fertility in women with HIV-1 infection in Uganda Lancet 1998 351 9096 98 103 (Pubitemid 28026636)
2. Homsy J., Bunnell R., Moore D., King R., Malamba S., Nakityo R., Glidden D., Tappero J., Mermin J., Reproductive intentions and outcomes among women on antiretroviral therapy in rural Uganda: a prospective cohort study PLoS ONE 2009 4 1
3. Myer L., Carter R. J., Katyal M., Toro P., El-Sadr W. M., Abrams E. J., Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study PLoS Medicine 2010 7 2
4. van Leth F., Phanuphak P., Ruxrungtham K., Baraldi E., Miller S., Gazzard B., Cahn P., Lalloo U. G., Van Der Westhuizen I. P., Malan D. R., Johnson M. A., Santos B. R., Mulcahy F., Wood R., Levi G. C., Reboredo G., Squires K., Cassetti I., Petit D., Raffi F., Katlama C., Murphy R. L., Horban A., Dam J. P., Hassink E., Van Leeuwen R., Robinson P., Wit F. W., Lange J. M. A., Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study Lancet 2004 363 9417 1253 1263 (Pubitemid 38496486)
5. SUSTIVA, Important Change in SUSTIVA (efavirenz) Package Insert- Change from Pregnancy Category C to D 2005 Washington, DC, USA SUSTIVA
6. SUSTIVA, Updated Label Information for Sustiva (efavirenz) 2010 Washington, DC, USA SUSTIVA
7. Ford N., Mofenson L., Kranzer K., Medu L., Frigati L., Mills E. J., Calmy A., Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts AIDS 2010 24 10 1461 1470
8. World Health Organization, A Systematic Review of the Teratogenicity of Efavirenz 2009 Geneva, Switzerland World Health Organization
9. Ford N., Calmy A., Mofenson L., Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis AIDS 2011 25 18 2301 2304
10. Ekouevi D. K., Coffie P. A., Ouattara E., Moh R., Amani-Bosse C., Messou E., Sissoko M., Anglaret X., Eholié S. P., Danel C., Dabis F., Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS databases, abidjan, Cte d'Ivoire Journal of Acquired Immune Deficiency Syndromes 2011 56 2 183 187
11. Bera E., McCausland K., Nonkwelo R., Mgudlwa B., Chacko S., Majeke B., Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional south african hospital AIDS 2010 24 2 283 289
12. World Health Organization, Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach-2010 rev 2010 Geneva, Switzerland World Health Organization
13. South African Department of Health, Clinical Guidelines for the Management of HIV AIDS in Adults and Adolescents 2010 Cape Town, South Africa South African Department of Health
14. Schwartz S. R., Mehta S. H., Taha T. E., Rees H. V., Venter F., Black V., High Pregnancy Intentions and Missed Opportunities for Patient-Provider Communication About Fertility in a South African Cohort of HIV-Positive Women on Antiretroviral Therapy AIDS and Behavior 2011 1 10
15. Nanda K., Morrison C. S., Kwok C., Byamugisha J., Jones L., Sriplienchan S., Magwali T., Discontinuation of oral contraceptives and depot medroxyprogesterone acetate among women with and without HIV in Uganda, Zimbabwe and Thailand Contraception 2011 83 6 542 548
16. van Leth F., Andrews S., Grinsztejn B., Wilkins E., Lazanas M. K., Lange J. M. A., Montaner J., The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART AIDS 2005 19 5 463 471 (Pubitemid 40515849)
17. De Lazzari E., Len A., Arnaiz J. A., Martinez E., Knobel H., Negredo E., Clotet B., Montaner J., Storfer S., Asenjo M. A., Mallolas J., Mir J. M., Gatell J. M., Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts HIV Medicine 2008 9 4 221 226 (Pubitemid 351467795)
18. Antela A., Ocampo A., Gmez R., Lpez M. J., Mario A., Losada E., Rodrguez R., Fernndez R., Corredoira J. C., Naval G., Rodrguez A., Miralles C., Prieto A., Liver toxicity after switching or simplifying to nevirapine-based therapy is not related to cd4 cell counts: results of the TOSCANA study HIV Clinical Trials 2010 11 1 11 17
19. Ouattara E. N., Anglaret X., Wong A. Y., Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age AIDS 2012 26 5 625 634
20. British HIV Association (BHIVA), Guidelines for the Management of HIV Infection in Pregnant Women 2012. Working Draft 2012 London, UK British HIV Association
21. Schouten E. J., Jahn A., Midiani D., Makombe S. D., Mnthambala A., Chirwa Z., Harries A. D., Van Oosterhout J. J., Meguid T., Ben-Smith A., Zachariah R., Lynen L., Zolfo M., Van Damme W., Gilks C. F., Atun R., Shawa M., Chimbwandira F., Prevention of mother-to-child transmission of HIV and the health-related millennium development goals: time for a public health approach The Lancet 2011 378 9787 282 284
22. Kitahata M. M., Gange S. J., Abraham A. G., Merriman B., Saag M. S., Justice A. C., Hogg R. S., Deeks S. G., Eron J. J., Brooks J. T., Rourke S. B., Gill M. J., Bosch R. J., Martin J. N., Klein M. B., Jacobson L. P., Rodriguez B., Sterling T. R., Kirk G. D., Napravnik S., Rachlis A. R., Calzavara L. M., Horberg M. A., Silverberg M. J., Gebo K. A., Goedert J. J., Benson C. A., Collier A. C., Van Rompaey S. E., Crane H. M., McKaig R. G., Lau B., Freeman A. M., Moore R. D., Effect of early versus deferred antiretroviral therapy for HIV on survival New England Journal of Medicine 2009 360 18 1815 1826
23. Cohen M. S., Chen Y. Q., McCauley M., Gamble T., Hosseinipour M. C., Kumarasamy N., Hakim J. G., Kumwenda J., Grinsztejn B., Pilotto J. H. S., Godbole S. V., Mehendale S., Chariyalertsak S., Santos B. R., Mayer K. H., Hoffman I. F., Eshleman S. H., Piwowar-Manning E., Wang L., Makhema J., Mills L. A., de Bruyn G., Sanne I., Eron J., Gallant J., Havlir D., Swindells S., Ribaudo H., Elharrar V., Burns D., Taha T. E., Nielsen-Saines K., Celentano D., Essex M., Fleming T. R., Prevention of HIV-1 infection with early antiretroviral therapy New England Journal of Medicine 2011 365 6 493 505